JP2016513124A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513124A5
JP2016513124A5 JP2015558976A JP2015558976A JP2016513124A5 JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5 JP 2015558976 A JP2015558976 A JP 2015558976A JP 2015558976 A JP2015558976 A JP 2015558976A JP 2016513124 A5 JP2016513124 A5 JP 2016513124A5
Authority
JP
Japan
Prior art keywords
compound
salt
pharmaceutical composition
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015558976A
Other languages
English (en)
Japanese (ja)
Other versions
JP6277210B2 (ja
JP2016513124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/017534 external-priority patent/WO2014130752A2/en
Publication of JP2016513124A publication Critical patent/JP2016513124A/ja
Publication of JP2016513124A5 publication Critical patent/JP2016513124A5/ja
Application granted granted Critical
Publication of JP6277210B2 publication Critical patent/JP6277210B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015558976A 2013-02-21 2014-02-21 二環式化合物 Expired - Fee Related JP6277210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
US61/767,531 2013-02-21
PCT/US2014/017534 WO2014130752A2 (en) 2013-02-21 2014-02-21 Bicyclic compounds

Publications (3)

Publication Number Publication Date
JP2016513124A JP2016513124A (ja) 2016-05-12
JP2016513124A5 true JP2016513124A5 (enExample) 2017-03-16
JP6277210B2 JP6277210B2 (ja) 2018-02-07

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015558976A Expired - Fee Related JP6277210B2 (ja) 2013-02-21 2014-02-21 二環式化合物

Country Status (34)

Country Link
US (3) US9115054B2 (enExample)
EP (1) EP2958888B1 (enExample)
JP (1) JP6277210B2 (enExample)
KR (1) KR102242265B1 (enExample)
CN (1) CN105026362B (enExample)
AR (1) AR094851A1 (enExample)
AU (1) AU2014218883B2 (enExample)
BR (1) BR112015019919A2 (enExample)
CA (1) CA2902168C (enExample)
CL (1) CL2015002358A1 (enExample)
CY (1) CY1118641T1 (enExample)
DK (1) DK2958888T3 (enExample)
EA (1) EA025294B1 (enExample)
ES (1) ES2613262T3 (enExample)
HR (1) HRP20170247T1 (enExample)
HU (1) HUE031626T2 (enExample)
IL (1) IL240613B (enExample)
LT (1) LT2958888T (enExample)
MA (1) MA38425B1 (enExample)
MX (1) MX2015010347A (enExample)
MY (1) MY173990A (enExample)
PE (1) PE20151746A1 (enExample)
PH (1) PH12015501793A1 (enExample)
PL (1) PL2958888T3 (enExample)
PT (1) PT2958888T (enExample)
RS (1) RS55703B1 (enExample)
SG (1) SG11201506408TA (enExample)
SI (1) SI2958888T1 (enExample)
SM (2) SMT201700115T1 (enExample)
TN (1) TN2015000356A1 (enExample)
TW (1) TWI613182B (enExample)
UY (1) UY35338A (enExample)
WO (1) WO2014130752A2 (enExample)
ZA (1) ZA201506965B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3022176B8 (en) 2013-07-15 2019-12-25 The Regents of the University of California Azacyclic constrained analogs of fty720
UY36274A (es) * 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
WO2017053990A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
US10633354B2 (en) 2016-09-02 2020-04-28 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
WO2019032632A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company ALKYLPHENYL COMPOUNDS
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
WO2021062168A1 (en) * 2019-09-25 2021-04-01 The Regents Of The University Of California Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU2003207567B2 (en) 2002-01-18 2008-01-24 Merck Sharp & Dohme Corp. Edg receptor agonists
US7351725B2 (en) 2002-01-18 2008-04-01 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
WO2003061567A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク エンド カムパニー インコーポレーテッド Edg受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
ES2467160T3 (es) 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション S1P(Edg)受容体作働薬としての(3,4−ジ置換)プロパンカルボン酸
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
EP1863463A1 (en) 2005-02-14 2007-12-12 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups
EP1858840A2 (en) 2005-02-18 2007-11-28 Innodia Inc. Analogs of 4-hydroxyisoleucine and uses thereof
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
PT1863474E (pt) 2005-03-23 2009-01-20 Actelion Pharmaceuticals Ltd Novos derivados de tiofeno como agonistas dos receptores 1 de esfingosina-1-fosfato
DE602006015297D1 (de) 2005-04-22 2010-08-19 Daiichi Sankyo Co Ltd 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用
EP1917240A1 (en) 2005-08-23 2008-05-07 Irm Llc Immunosuppressant compounds and compositions
JP5432526B2 (ja) 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
BRPI0707281A2 (pt) 2006-01-27 2011-04-26 Univ Virginia método para prevenção ou tratamento de dor neuropática em um mamìfero
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
CL2007000742A1 (es) 2006-03-21 2008-01-11 Epix Delaware Inc Compuestos derivados de 2-oxoimidazol, moduladores del recptor s1p (esfingosina-1-fosfato); composicion farmceutica que los contiene; y su uso para tratar condiciones tales como rechazo de trasplante, cancer, artritis reumatoide y diabetes.
WO2007111864A2 (en) 2006-03-23 2007-10-04 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
JP2010513532A (ja) * 2006-12-21 2010-04-30 アボット・ラボラトリーズ スフィンゴシン−1−ホスフェート受容体作働薬および拮抗薬化合物
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
KR101174191B1 (ko) 2007-02-02 2012-08-14 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료용 taar1 리간드로서 2-아미노옥사졸린
WO2008114157A1 (en) 2007-03-16 2008-09-25 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009124022A1 (en) 2008-04-01 2009-10-08 Theravance, Inc. 2 -aminotetralin derivatives as mu opioid receptor antagonists
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
AU2009327133B2 (en) 2008-12-18 2016-04-14 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en) 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
EP2382212B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2382211B1 (en) 2009-01-23 2012-12-19 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
CN102361869A (zh) * 2009-01-23 2012-02-22 百时美施贵宝公司 在治疗自身免疫性疾病和炎性疾病中作为s1p激动剂的取代的噁二唑衍生物
CN102316862A (zh) 2009-02-10 2012-01-11 雅培制药有限公司 制备s1p受体激动剂或拮抗剂的方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
KR20130036171A (ko) 2009-10-29 2013-04-11 브리스톨-마이어스 스큅 컴퍼니 트리시클릭 헤테로시클릭 화합물
CN103119038B (zh) 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1,2,4-噁二唑基-3-基)扁桃酰胺
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
EP2635573B1 (en) 2010-11-03 2014-10-01 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
EP2685971A4 (en) 2011-03-18 2014-01-22 Univ Virginia Patent Found COMPOSITIONS AND METHODS FOR TISSUE PROCESSING AND CELL-BASED THERAPIES
EP2541155B1 (en) 2011-04-26 2016-02-24 Panasonic Intellectual Property Management Co., Ltd. Heating system, and heating system control method
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
KR102127025B1 (ko) 2012-07-27 2020-06-25 비오겐 엠에이 아이엔씨. S1p 조절제 및/또는 atx 조절제인 화합물들

Similar Documents

Publication Publication Date Title
JP2016513124A5 (enExample)
RU2016105581A (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
JP2016528301A5 (enExample)
JP2016539134A5 (enExample)
AR101177A1 (es) Inhibidores de la syk
AR088458A1 (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod
JP2010174019A5 (enExample)
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
JP2017514910A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
IL292465B2 (en) Neuroactive compounds and methods of use thereof
RU2019121667A (ru) Аминопиразолы в качестве селективных ингибиторов янус-киназы
JP2013518036A5 (enExample)
JP2017511377A5 (enExample)
JP2019516739A5 (enExample)
RU2017106172A (ru) Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
JP2014513065A5 (enExample)
BR112017017211A2 (pt) composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto.
BR112015019919A2 (pt) compostos bicíclicos
RU2015135824A (ru) Бициклические соединения пиримидона в качестве ингибиторов lp-pla2
BR112012022632A2 (pt) Medicamento compreendendo agonista de ep4
JP2019052094A5 (enExample)